Cogent Biosciences, Inc. (NASDAQ: COGT) surged 17.28% following positive top-line results from SUMMIT clinical trial in pre-market trading on Monday, July 7, 2025, reaching $8.89 per share. This marks a notable rise from the previous closing price of $7.58.
Cogent Biosciences, Inc. (COGT) announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis. The trial demonstrated clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints. These endpoints include patient-reported symptoms and objective measures of mast cell burden.
